N27: The Management Of Gynaecological Cancers In Lynch Syndrome: The Manchester International Consensus Meeting

E. J. Crosbie1, N. A. J. Crosbie1, D. G. Evans1, Manchester International Consensus Group2

1 – University of Manchester. 2 – Manchester International Consensus Group.


Aim: There are no internationally agreed clinical guidelines as to how best to manage the risk, prevention and treatment of gynaecological cancers in women with Lynch syndrome. The Manchester International Consensus Group was convened in April 2017 to develop clear and comprehensive clinical guidance regarding the management of the gynaecological sequelae of Lynch syndrome based on existing evidence and expert opinion from medical professionals and patients.

Method: Stakeholders from Europe and North America worked together over a two-day workshop to achieve consensus on best practice. Stakeholders included patients, patient support groups, gynaecologists, clinical geneticists, medical oncologists, colorectal surgeons, gastroenterologists, histopathologists, genetic pathologists, health economists, epidemiologists, gynaecology nurse specialists and genetic counsellors.

Results: Guidance was developed in four key areas: 1) whether women with gynaecological cancer should be screened for Lynch syndrome and 2) how this should be done; 3) whether gynaecological surveillance was of value for women with Lynch syndrome; and 4) what preventive measures should be recommended for women with Lynch syndrome to reduce their gynaecological cancer risk.

Conclusion: The Manchester International Consensus Guideline provides comprehensive clinical guidance that can be referenced by both patients and clinicians so that women with Lynch syndrome can expect and receive appropriate standards of care.